Dramatic changes in catestatin are associated with hemodynamics in acute myocardial infarction

References

• Angelone T, Quintieri AM, Brar BK, Limchaiyawat PT, Tota B, Mahata SK, Cerra MC. (2008). The antihypertensive chromogranin a peptide catestatin acts as a novel endocrine/paracrine modulator of cardiac inotropism and lusitropism. Endocrinology 149:4780–4793.
   PubMed Web of Science ®Google Scholar
• Bacaner M, Brietenbucher J, LaBree J. (2004). Prevention of ventricular fibrillation, acute myocardial infarction (myocardial necrosis), heart failure, and mortality by bretylium: is ischemic heart disease primarily adrenergic cardiovascular disease? Am J Ther 11:366–411.
   PubMedGoogle Scholar
• Biswas N, Curello E, O’Connor DT, Mahata SK. (2010). Chromogranin/secretogranin proteins in murine heart: myocardial production of chromogranin A fragment catestatin (Chga(364-384)). Cell Tissue Res 342:353–361.
   PubMed Web of Science ®Google Scholar
• Biswas N, Rodriguez-Flores JL, Courel M, Gayen JR, Vaingankar SM, Mahata M, Torpey JW, Taupenot L, O’Connor DT, Mahata SK. (2009). Cathepsin L colocalizes with chromogranin a in chromaffin vesicles to generate active peptides. Endocrinology 150:3547–3557.
   PubMed Web of Science ®Google Scholar
• Biswas N, Vaingankar SM, Mahata M, Das M, Gayen JR, Taupenot L, Torpey JW, O’Connor DT, Mahata SK. (2008). Proteolytic cleavage of human chromogranin a containing naturally occurring catestatin variants: differential processing at catestatin region by plasmin. Endocrinology 149:749–757.
   PubMed Web of Science ®Google Scholar
• Brar BK, Helgeland E, Mahata SK, Zhang K, O’Connor DT, Helle KB, Jonassen AK. (2010). Human catestatin peptides differentially regulate infarct size in the ischemic-reperfused rat heart. Regul Pept 165:63–70.
   PubMed Web of Science ®Google Scholar
• Ceconi C, Ferrari R, Bachetti T, Opasich C, Volterrani M, Colombo B, Parrinello G, Corti A. (2002). Chromogranin A in heart failure; a novel neurohumoral factor and a predictor for mortality. Eur Heart J 23:967–974.
   PubMed Web of Science ®Google Scholar
• Cryer PE. (1992). Pheochromocytoma. West J Med 156:399–407.
   PubMedGoogle Scholar
• Dev NB, Gayen JR, O’Connor DT, Mahata SK. (2010). Chromogranin a and the autonomic system: decomposition of heart rate variability and rescue by its catestatin fragment. Endocrinology 151:2760–2768.
   PubMed Web of Science ®Google Scholar
• Estensen ME, Hognestad A, Syversen U, Squire I, Ng L, Kjekshus J, Dickstein K, Omland T. (2006). Prognostic value of plasma chromogranin A levels in patients with complicated myocardial infarction. Am Heart J 152:927.e1–927.e6.
   PubMed Web of Science ®Google Scholar
• Foy SG, Crozier IG, Richards AM, Nicholls MG, Turner JG, Frampton CM, Ikram H. (1995). Neurohormonal changes after acute myocardial infarction. Relationships with haemodynamic indices and effects of ACE inhibition. Eur Heart J 16:770–778.
   PubMed Web of Science ®Google Scholar
• Fung MM, Salem RM, Mehtani P, Thomas B, Lu CF, Perez B, Rao F, Stridsberg M, Ziegler MG, Mahata SK, O’Connor DT. (2010). Direct vasoactive effects of the chromogranin A (CHGA) peptide catestatin in humans in vivo. Clin Exp Hypertens 32:278–287.
   PubMed Web of Science ®Google Scholar
• Gayen JR, Gu Y, O’Connor DT, Mahata SK. (2009). Global disturbances in autonomic function yield cardiovascular instability and hypertension in the chromogranin a null mouse. Endocrinology 150:5027–5035.
   PubMed Web of Science ®Google Scholar
• Jansson AM, Røsjø H, Omland T, Karlsson T, Hartford M, Flyvbjerg A, Caidahl K. (2009). Prognostic value of circulating chromogranin A levels in acute coronary syndromes. Eur Heart J 30:25–32.
   PubMed Web of Science ®Google Scholar
• Karlsberg RP, Cryer PE, Roberts R. (1981). Serial plasma catecholamine response early in the course of clinical acute myocardial infarction: relationship to infarct extent and mortality. Am Heart J 102:24–29.
   PubMed Web of Science ®Google Scholar
• Lee JC, Taylor CV, Gaucher SP, Toneff T, Taupenot L, Yasothornsrikul S, Mahata SK, Sei C, Parmer RJ, Neveu JM, Lane WS, Gibson BW, O’Connor DT, Hook VY. (2003). Primary sequence characterization of catestatin intermediates and peptides defines proteolytic cleavage sites utilized for converting chromogranin a into active catestatin secreted from neuroendocrine chromaffin cells. Biochemistry 42:6938–6946.
   PubMed Web of Science ®Google Scholar
• Mahapatra NR, Mahata M, Hazra PP, McDonough PM, O’Connor DT, Mahata SK. (2004). A dynamic pool of calcium in catecholamine storage vesicles. Exploration in living cells by a novel vesicle-targeted chromogranin A-aequorin chimeric photoprotein. J Biol Chem 279:51107–51121.
   PubMed Web of Science ®Google Scholar
• Mahapatra NR, Mahata M, Mahata SK, O’Connor DT. (2006). The chromogranin A fragment catestatin: specificity, potency and mechanism to inhibit exocytotic secretion of multiple catecholamine storage vesicle co-transmitters. J Hypertens 24:895–904.
   PubMed Web of Science ®Google Scholar
• Mahapatra NR, O’Connor DT, Vaingankar SM, Hikim AP, Mahata M, Ray S, Staite E, Wu H, Gu Y, Dalton N, Kennedy BP, Ziegler MG, Ross J, Mahata SK. (2005). Hypertension from targeted ablation of chromogranin A can be rescued by the human ortholog. J Clin Invest 115:1942–1952.
   PubMed Web of Science ®Google Scholar
• Mahata SK, Mahapatra NR, Mahata M, Wang TC, Kennedy BP, Ziegler MG, O’Connor DT. (2003). Catecholamine secretory vesicle stimulus-transcription coupling in vivo. Demonstration by a novel transgenic promoter/photoprotein reporter and inhibition of secretion and transcription by the chromogranin A fragment catestatin. J Biol Chem 278:32058–32067.
   PubMed Web of Science ®Google Scholar
• Mahata SK, Mahata M, Wakade AR, O’Connor DT. (2000). Primary structure and function of the catecholamine release inhibitory peptide catestatin (chromogranin A(344-364)): identification of amino acid residues crucial for activity. Mol Endocrinol 14:1525–1535.
   PubMedGoogle Scholar
• Mahata SK, O’Connor DT, Mahata M, Yoo SH, Taupenot L, Wu H, Gill BM, Parmer RJ. (1997). Novel autocrine feedback control of catecholamine release. A discrete chromogranin a fragment is a noncompetitive nicotinic cholinergic antagonist. J Clin Invest 100:1623–1633.
   PubMed Web of Science ®Google Scholar
• O’Connor DT, Kailasam MT, Kennedy BP, Ziegler MG, Yanaihara N, Parmer RJ. (2002). Early decline in the catecholamine release-inhibitory peptide catestatin in humans at genetic risk of hypertension. J Hypertens 20:1335–1345.
   PubMed Web of Science ®Google Scholar
• Petersen CL, Nielsen JR, Petersen BL, Kjaer A. (2003). Catecholaminergic activation in acute myocardial infarction: time course and relation to left ventricular performance. Cardiology 100:23–28.
   PubMed Web of Science ®Google Scholar
• Pfeifer K, Boe SP, Rong Q, Ebert SN. (2004). Generating mouse models for studying the function and fate of intrinsic cardiac adrenergic cells. Ann N Y Acad Sci 1018:418–423.
   PubMed Web of Science ®Google Scholar
• Rao F, Wen G, Gayen JR, Das M, Vaingankar SM, Rana BK, Mahata M, Kennedy BP, Salem RM, Stridsberg M, Abel K, Smith DW, Eskin E, Schork NJ, Hamilton BA, Ziegler MG, Mahata SK, O’Connor DT. (2007). Catecholamine release-inhibitory peptide catestatin (chromogranin A(352-372)): naturally occurring amino acid variant Gly364Ser causes profound changes in human autonomic activity and alters risk for hypertension. Circulation 115:2271–2281.
   PubMed Web of Science ®Google Scholar
• Rouleau JL, Moyé LA, de Champlain J, Klein M, Bichet D, Packer M, Dagenais G, Sussex B, Arnold JM, Sestier F. (1991). Activation of neurohumoral systems following acute myocardial infarction. Am J Cardiol 68:80D–86D.
   PubMedGoogle Scholar
• Sigurdsson A, Held P, Swedberg K. (1993). Short- and long-term neurohormonal activation following acute myocardial infarction. Am Heart J 126:1068–1076.
   PubMed Web of Science ®Google Scholar
• Taylor CV, Taupenot L, Mahata SK, Mahata M, Wu H, Yasothornsrikul S, Toneff T, Caporale C, Jiang Q, Parmer RJ, Hook VY, O’Connor DT. (2000). Formation of the catecholamine release-inhibitory peptide catestatin from chromogranin A. Determination of proteolytic cleavage sites in hormone storage granules. J Biol Chem 275:22905–22915.
   PubMed Web of Science ®Google Scholar
• Waldenström AP, Hjalmarson AC, Thornell L. (1978). A possible role of noradrenaline in the development of myocardial infarction: an experimental study in the isolated rat heart. Am Heart J 95:43–51.
   PubMed Web of Science ®Google Scholar